DelveInsight’s, “Exosomes - Pipeline Insight, 2022,” report provides comprehensive insights about 55+ companies and 70+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Exosomes: Overview
Exosomes are a type of extracellular vesicle, a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages that contain constituents (protein, DNA, and RNA) of the cells that secrete them. Exosomes can be a highly heterogeneous population and have distinct abilities to induce a complex biological response. Exosomes are isolated from a wide spectrum of biological fluids, including blood, urine, saliva and breast milk. Exosomes are generated in a process that involves double invagination of the plasma membrane and the formation of intracellular multivesicular bodies containing intraluminal vesicles. Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes have therapeutic potential to control many diseases, along with aid in disease diagnosis. Extensive studies are going on for the role of exosomes in the diagnosis and treatment of various pathologies.
The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches for Exosomes.
This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Exosomes Emerging Drugs
ExoFlo: Direct Biologics
ExoFlo is an investigational new drug that has not been approved or licensed by the FDA. It is an extracellular vesicle product isolated from human bone marrow mesenchymal stem or stromal cells (MSCs). The drug is in Phase II clinical development for the treatment of Covid19, ARDS, and viral pneumonia. In October 2020, The US Food and Drug Administration (FDA) granted expanded access for Direct Biologics’ ExoFlo, allowing it to be used to treat patients with COVID-19-associated acute respiratory distress syndrome. It is currently in phase II stage of development and is being developed by Direct Biologics.
Progenza: Regeneus
Progenza is being developed by Regeneus, and is currently in the Phase II stage of development for Osteoarthritis and preclinical for Neuropathic Pain. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue but the Mesenchymal Signalling Cells (MSCs) themselves.
Further product details are provided in the report……..
This segment of the report provides insights about the different Exosomes drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 55+ key companies which are developing the Exosomes. The companies which have their Exosomes drug candidates in the most advanced stage, i.e. Phase II include, Direct Biologics.
DelveInsight’s report covers around 70+ products under different phases of clinical development like
Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Exosomes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ExoFlo: Direct Biologics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
UNEX 42: United Therapeutics
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
EVX-102: Evox Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Exosomes Key Companies
Exosomes Key Products
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Exosomes- Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix
List of Table
Table 1: Total Products for Exosomes
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Exosomes
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Direct Biologics
• Capricor
• Regeneus
• AVEM HealthCare
• Aegle Therapeutics
• Organicell Regenerative Medicine
• Codiak Biosciences
• United Therapeutics
• ArunA Biomedical
• Evox Therapeutics
• ArunA Biomedical
• MolecuVax
• Versatope Therapeutics
• Lamellar Biomedical
• Azymus Therapeutics
• Alxerion Biotech
• Avalon GloboCare
• Capricor Therapeutics
